Hemorrhagic cystitis (HC) is a common complication after allogeneic hematopoietic SCT (allo-HSCT). Several risk factors have been suggested including BU-containing myeloablative conditioning, unrelated donors and GVHD, but these have not been consistently reported. We conducted a retrospective study including 339 allo-HSCT recipients between 2009 and 2012. Of 339 patients, 79 (23.3%) developed HC with 2-year cumulative incidence of 24.0% (95% confidence interval, 19.4-28.9). The median onset time was 45 days (range, 16-430) after allo-HSCT. Sixty-two patients (84%) out of 74 evaluated for urine BK virus PCR testing showed a positive result (mean 2.0 × 10 10 copies of DNA per mL). In univariate analysis, myeloablative conditioning, HLA-mismatched donor, CMV viremia and acute GVHD (aGVHD) grade 3-4 were significantly associated with the risk of HC. Multivariate analysis confirmed all associating factors identified in univariate analysis except for HLA-mismatched donor: myeloablative conditioning (hazard ratio (HR) 2.63, P = 0.003), CMV viremia (HR 1.88, P = 0.014) and aGVHD grade 3-4 (HR 1.71, P = 0.029). HC did not affect OS or non-relapse mortality. Symptomatic HC is a frequent complication following allo-HSCT, with a 2-year cumulative incidence of 24.0%. Three clinical factors associated with HC were identified including myeloablative conditioning, CMV viremia and severe aGVHD.
INTRODUCTION
Hemorrhagic cystitis (HC) is one of the common complications after allogeneic hematopoietic SCT (allo-HSCT) with the reported incidence varying from 7 to 70%. [1] [2] [3] [4] [5] [6] While early-onset HC is usually mild with microscopic hematuria and secondary to the chemoradiation (e.g., CY), more severe HC with gross hematuria develops in the later course of allo-HSCT (⩾30 days after transplant) and is strongly associated with BK virus. 1, 3, [7] [8] [9] [10] [11] [12] Polyomavirus BK (BKV) is a double-stranded non-enveloped DNA virus first isolated from a urine sample obtained from a renal transplant recipient. [13] [14] [15] Primary infection occurs in childhood and remains in a latent phase most commonly in the kidney. [16] [17] [18] [19] The reactivation of the latent virus is observed in patients with immunodeficiency. 19, 20 The two most important diseases are BKV-associated nephropathy in renal transplant and BKV-associated HC (BK-HC) in allo-HSCT. 21 Although the pathogenesis of BKV is not fully understood, it seems that it has a different pathogenesis in HSCT recipients where it more often presents as HC, compared with BKV nephropathy in renal transplant recipients. 21, 22 Several risk factors for HC associated with BKV after allo-HSCT have been suggested, such as conditioning regimens containing BU, acute GVHD (aGVHD), intensity of conditioning regimen, donor type, CMV seropositivity and post-transplant mycophenolate use. 4, 8, 10, 23, 24 However, these are yet to be confirmed.
We conducted an institutional retrospective study to analyze the incidence and clinical factors associated with BK-HC in allo-HSCT. . For related donors HLA-A, -B and -DR were screened, and for unrelated donors HLA-C and -DQ were added. Related donor transplants were not T-cell depleted. Unrelated donor transplants were T-cell depleted in vivo using antithymoglobulin Ab or alemtuzumab unless patients were enrolled in a clinical trial where they were randomized to a non-T-cell-depleted arm.
PATIENTS AND METHODS

Patients and allo-SCT
HC was defined as microscopic hematuria with the presence of lower urinary tract irritability or macroscopic hematuria. The severity of HC was retrospectively graded based on the severest symptoms and signs recorded in the medical record. HC was graded as follows: grade 1, microscopic hematuria with urinary symptoms; grade 2, macroscopic hematuria; grade 3, macroscopic hematuria with clots; and grade 4, macroscopic hematuria with intervention for clot evaluation and/or urinary retention. 1, 25, 26 Screening for microscopic hematuria was not routinely performed. Patients with any kind of urinary symptom were evaluated with routine urinalysis and urine culture to rule out bacterial infection. The definition of BK-HC was documented HC of any grade and BKV viruria defined as positive at any level by BKV quantitative PCR testing in urine. One hundred and forty-four patients (36.1%) out of 399 patients had BKV quantitative PCR testing performed on urine samples including 74 patients with at least grade 1 HC.
Statistics
The duration of clearance of HC-related symptoms was calculated from the date of diagnosis of HC to the date of freedom from urinary symptoms or the date of death from any cause, which ever occurred earlier.
The OS was calculated using the Kaplan-Meier method with log-rank test for univariate analysis and defined as the date of transplantation to the date of death or last follow-up. The OS between HC and non-HC groups was compared with the Kaplan-Meier method with Wilcoxon's test. The Cox proportional hazard regression model was used for the multivariate analysis of OS with the time-dependent covariate of occurrence of HC. The cumulative incidence of HC, aGVHD and non-relapse mortality (NRM) was estimated considering competing risks. Competing events were disease relapse for NRM, and disease relapse and NRM for aGVHD and HC. The univariate analysis for cumulative incidence with competing events was performed using Gray's method. Fine-Gray proportional hazard regression with competing events was used for multivariate analysis to confirm the factors associating with the risk of HC. The variables tested for the multivariate analyses included age, gender mismatch, GVHD prophylaxis, intensity of conditioning regimens, type of transplant, source of stem cells, aGVHD and CMV viremia. The variable was considered statistically significant when the P-value was o0.05.
The two-sample t-test and one-way analysis of variance test were used to compare the mean viral loads in urine samples. The repeated-measures analysis of variance test was performed to compare the mean creatinine at the onset of HC, at peak and after resolution of symptoms in patients who developed HC. Receiver operating characteristic curve analysis was used to identify the cutoff value of BKV viral loads in the urine to predict symptomatic BK-HC.
All statistical analyses were performed using EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan). 27 EZR is a modified version of R commander (version 1.8-4) (http://www.jichi.ac.jp/ saitama-sct/SaitamaHP.files/statmedEN.html).
RESULTS
Patient characteristics
Among 339 patients in the study cohort, 79 patients (23.3%) developed HC ( Table 1) . The majority of patients received fludarabine/BU/TBI-based regimens for myeloablative or nonmyeloablative conditioning; 157 patients (75.5%) out of 208 patients with myeloablative conditioning received FBT-400 and 107 patients (81.7%) out of 131 with non-myeloablative conditioning did FBT-200. There were no statistical differences in baseline characteristics between the HC and non-HC groups except intensity of conditioning regimen, CMV viremia and aGVHD. Among 217 patients with any grade aGVHD, 63 patients (29.0% of 79 HC patients) developed HC (P o0.001). With a median interval of 24 days from aGVHD occurrence to HC development, 45 patients out of 63 have developed aGVHD before the occurrence of HC. Among 18 patients who had HC before the occurrence of aGVHD, 11 have developed aGVHD within 2 weeks from the occurrence of HC. In addition, there was also strong correlation between the onsets of HC and CMV viremia as 29 patients of 50 with CMV viremia in HC cohort have developed HC within 3 weeks either prior or after the onset of CMV viremia.
The cumulative incidence of HC at 2 years was 24.0% (95% confidence interval (CI), 19.4-28.9; Figure 1a) Seventy-five of 79 patients were treated with oral or i.v. ciprofloxacin empirically. Fourteen patients required hospital admission for supportive care such as continuous bladder irrigation (n = 8, 10%) or i.v. pain management (n = 14, 18%). Three of them were treated with leflunomide and one with i.v. cidofovir. In the last case, the patient was infected with both BKV and adenovirus isolated in the urine. One patient received electrofulguration of the bladder owing to massive bleeding. There were no deaths directly attributable to HC.
The median duration of clearance of HC-related symptoms was 21 days (range, 6-232 days; Figure 1b ). Eighteen out of 79 HC patients (22.8%) did not have the resolution of HC symptoms until they died of either disease relapse (n = 6), GVHD (n = 10) or infection (n = 2). There was no difference in the duration of HC symptoms between BK-positive and -negative groups (P = 0.443).
Serum creatinine level showed the trend to increase during the course of HC. The mean creatinine level of HC patients (n = 79) was 81 μmol/L (95% CI, 74-87 μmol/L) at the onset, 121 μmol/L (95% CI, 107-135 μmol/L) at the peak and 97 μmol/L (95% CI 85-109-μmol/L) at the resolution of symptoms with statistical significance in differences (P o 0.001) (Figure 2a ).
Of note, the patients with CMV viremia (n = 50) had more significant increases in creatinine over the course of HC than those without CMV viremia (n = 29) (83, 127, 96 μmol/L and 77, 88, 76 μmol/L, P = 0.046) (Figure 2b ). This suggested that worsening of renal function during the course of HC was probably due to concurrent anti-CMV therapy, which is potentially nephrotoxic, rather than to HC itself.
BKV viruria Among 144 patients who had a urine test for BKV quantitative PCR results available, 74 had a diagnosis of HC. Five out of 79 HC patients did not have BKV urine PCR testing available. Sixty-two (84%) out of 74 patients with the diagnosis of HC and BKV urine test available were found to have BKV viruria by quantitative PCR, whereas 28 (40%) of 70 patients without HC were positive for BKV viruria.
There was no difference in transplant characteristics, aGVHD and CMV viremia rates between HC patients with BK viruria and those without viruria ( Table 1 Univariate and multivariate analyses for HC Univariate and multivariate analyses were performed to identify the factors associated with HC ( Table 2 ). The factors associated with HC in univariate analysis were myeloablative conditioning, mismatched transplant, CMV viremia and aGVHD grade 3-4.
Multivariate analysis confirmed the following factors associated with HC: myeloablative conditioning (hazard ratio (HR) 2.63, P = 0.003), CMV viremia (HR 1.88, P = 0.014) and aGVHD grade 3-4
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The risk factors for BK virus hemorrhagic cystitis after allogeneic SCT J Uhm et al (HR 1.71, P = 0.029). In addition to that, CMV viremia and aGVHD were strongly associated with the event of HC, the onset of the first CMV viremia and aGVHD were close to the onset of HC (median onset of CMV viremia, 51 days, 95% CI, 41-136 days; median onset of aGVHD, 40 days, 95% CI, 36-45 days).
As the majority of patients received BU-containing regimens either for myeloablative or non-myeloablative conditioning, the subgroup analysis for BK-HC including 254 patients with fludarabine/BU/TBI conditioning regimen was performed to identify the risk factors for BK-HC (Supplementary Table 1 ). The analysis confirmed aGVHD grade 3-4 (HR 1.89, P = 0.015) and myeloablative conditioning (HR 2.44, P = 0.013) as associated risk factors for BK-HC.
Transplantation outcomes
With median follow-up duration of 499 days (range, 45-1414 days), the OS at 1 year was 63.26% (95% CI, 57.5-68.3%). There was no difference in OS at 1 year between patients with vs without HC (56.4% vs 65.2%, P = 0.337; Figure 3a) . The confirmed adverse factors for OS were age (HR 1.019, P = 0.009), unrelated donor (HR 1.974, P o 0.001) and aGVHD grade 3-4 (HR 4.646, Po 0.001) in multivariate analysis, but HC was not confirmed.
The cumulative incidence of NRM at 1 year was 27.7% (95% CI, 22.8-32.8). Although a higher trend of NRM at 1 year was noted in the patients with HC than those without HC (39.7 vs 24.2%), this difference was not statistically significant (P = 0.19; Figure 3b ). In multivariate analysis for NRM, aGVHD grade 3-4 (HR 7.418, P o0.001) and unrelated donor (HR 2.336, P o 0.001) were identified as adverse factors. Age showed a borderline significance with an HR of 1.016 (P = 0.056). As in the case of OS, HC was not found to adversely affect NRM in multivariate analysis.
DISCUSSION
This study shows that (1) the incidence of HC is high (24%) in this study; (2) developing HC is strongly associated with severe aGVHD; (3) HC does not affect OS, but there is a trend toward a higher NRM in HC patients, which is likely due to its strong correlation with severe aGVHD as opposed to a causal relationship.
HC after allo-HSCT is a common complication that causes significant morbidity as well as is associated with increased hospital cost. 6, 28 The cumulative incidence of HC in this cohort was 24% at 2-year after allo-HSCT, which is comparable to other published reports. Post-engraftment HC is strongly associated with BKV, although the role of BKV in its pathogenesis has not yet been fully elucidated. 1, 3, 7, 8, 10, 11, 23, 24, [29] [30] [31] [32] In this study, BKV viruria was detected in 83.7% among patients who had urine PCR BKV testing in the presence of a diagnosis of HC. This is comparable to previously published rates of post-engraftment BKV viruria ranging from 79 to 100%. 3, 7, 10, 23 However, more than half of the patients remained asymptomatic with BKV viruria. 29, [33] [34] [35] With the advent of quantitative BKV PCR techniques, BKV load in the urine was quantitatively related to the occurrence of HC.
11, 29 Leung et al.
11 demonstrated that HC patients had approximately 10 5 times higher peak viruria and total viral excretion than non-HC patients. The present study also showed that there was a significant difference in the viral load between the patients with asymptomatic viruria and symptomatic patients with BK-HC.
Interestingly, Wong et al. 32 showed anti-BKV IgG (⩾1:20) pre-HSCT had a significant correlation with maximum urine BKV load during HSCT. Along with the quantitative correlation between BKV viruria and the development of HC, this may suggest that the host immune response has an important role in the reactivation of BKV in uroepithelium and the subsequent development of HC. 36 Many studies have tried to identify the risk factors for BK-HC in allo-HSCT. 1, 3, 4, 10, 23, 24, 28, 31, 32, 37 Older age was identified as a risk factor in pediatric HSCTs, 2, 3, 31 but no other risk factor has been consistently verified in adult HSCTs, although aGVHD, BU-based conditioning regimens, the type of HSCT and the intensity of conditioning have been suggested. 4, 10, 23, 24, 26, 30, 32 Most recently, Rorije et al. 4 reported a single-center, retrospective study. Among 491 allo-HSCT recipients, 78 (15.9%) patients developed BK-HC. aGVHD grade 2-4, cord blood HSCT, post-transplant Abbreviations: CI = confidence interval; HR = hazard ratio.
The risk factors for BK virus hemorrhagic cystitis after allogeneic SCT J Uhm et al mycophenolate and high-dose CY conditioning were identified as the risk factors for BK-HC. Gilis et al. 28 also reported cord blood HSCT as a risk factor for BK-HC along with PBSCT. In the present study, multivariate analysis confirmed that myeloablative conditioning, CMV viremia and severe aGVHD are associated with HC in allo-HSCT, but no association between HC and stem cell source or the type of transplant. However, the difference in study cohorts should be noted as the current study did not include cord blood HSCT and the most of patients received PBSCT. HLA-mismatched donor shown in the analysis among the group with mycophenolate and calcineurin inhibitor might support the alternate donor as a risk factor for HC as Rorije et al. 4 and Gilis et al. 28 have suggested (Supplementary Table 2 ).
Considering that the majority of post-engraftment HC was related with BKV viruria, the associated factors for post-engraftment HC (myeloablative conditioning, severe aGVHD and CMV viremia) may support the theory that the development of BK-HC is the consequence of events related to those risk factors reflecting severe immunosuppression and defective urothelial protection. Myeloablative conditioning could be more damaging to the urothelium than non-myeloablative conditioning. The replication of BKV would then cause the denudation of damaged urothelial mucosa. 22 The immunocompromised status allows uncontrolled replication of BKV resulting in a rise of BKV viral load in the urine, and subsequently developing HC. BU has been implicated as a risk factor for HC but a dose-dependent correlation has not been reported. 10, [37] [38] [39] In this study, the subgroup analysis including fludarabine/BU/TBI conditioning showed myeloablative conditioning regimen as a risk factor for HC in multivariate analysis. This analysis could support the dose dependence of BU on the development of BK-HC as Gilis et al. 28 suggested a conditioning regimen including 4 days of BU for a risk factor for BK-HC.
Although there have been previous reports that failed to demonstrate the correlation between aGVHD and HC, 1, 3, 11, 24, 28 this study showed aGVHD grade 3-4 was strongly associated with the risk of BK-HC. As patients who developed severe aGVHD are treated with higher and more prolonged doses of systemic glucocorticosteroids than the patients with mild aGVHD, intensive immunosuppressive treatment for aGVHD and/or immunosuppression from GVHD itself could contribute to uncontrolled BKV replication, as well as CMV viremia. In regards to the strong correlation among aGVHD, CMV viremia and BK-HC, the further study would be warranted to research whether the immunologic response contributing aGVHD also could have a role in the development of HC.
CMV viremia reflects impaired T-cell immunity and weak T-cell responses were linked to recurrent BKV viremia in renal transplant recipients. 20, 40 However, applying observations from renal transplant patients to HSCT patients needs to be carried out with caution. Li et al. 22 showed that the BKV-associated urothelial cell damage is different from renal tubular epithelial cell damage with a slower replication cycle and less progeny virus released. This suggests that the pathogenesis of BK-HC may be different to BKV nephropathy seen in more commonly in renal transplant patients. 22 In conclusion, this study demonstrated that HC is a common complication in adult allo-HSCT patients. Myeloablative conditioning, severe aGVHD grade 3-4 and CMV viremia were associated with the development of HC. Although HC did not adversely impact survival, it is associated with significant morbidity and is still clinically difficult to manage as there are no effective antiviral treatments available.
